GlassScriptPhysician profile
Thomas J Andrews
NPI 1245393651
$15,621.44
in general payments reported to CMS, 2019-2025
28 companies · $702 in 2025
The $702 reported for 2025 was more than what 76% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,036 · 2020: $860 · 2021: $700 · 2022: $788 · 2023: $6,568 · 2024: $4,966 · 2025: $702.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $9,750 · Food and Beverage: $2,487.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $9,750.00 |
| Food and Beverage | $2,486.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $8,442.54 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Almatica Pharma LLC | $2,145.73 | 2021-2024 | Loreev Xr |
| Abbvie INC. | $1,001.97 | 2021-2025 | Vraylar |
| Sunovion Pharmaceuticals INC. | $591.53 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $486.02 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $481.38 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $441.08 | 2020-2025 | Spravato |
| Allergan, INC. | $360.88 | 2019-2020 | |
| Axsome Therapeutics, INC. | $207.60 | 2022-2025 | Auvelity |
| Corium, LLC | $187.86 | 2022-2024 | Azstarys |
| Otsuka America Pharmaceutical, INC. | $187.19 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $128.98 | 2020-2025 | Caplyta |
| Eisai INC. | $117.04 | 2020-2021 | |
| Neuronetics, INC. | $115.65 | 2021-2025 | Neurostar Tms Therapy System |
| Idorsia Pharmaceuticals US INC | $114.53 | 2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $108.88 | 2021-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $94.73 | 2020-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $81.30 | 2020-2024 | Hetlioz, Fanapt |
| Ironshore Pharmaceuticals INC. | $69.12 | 2019-2024 | |
| Avanir Pharmaceuticals, INC. | $68.15 | 2019 | |
| Lundbeck LLC | $46.75 | 2019-2024 | Rexulti |
| Supernus Pharmaceuticals, INC. | $22.72 | 2025 | Qelbree |
| Harmony Biosciences LLC | $22.59 | 2022 | |
| Jazz Pharmaceuticals INC. | $22.33 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.83 | 2025 | Cobenfy |
| Indivior INC. | $20.12 | 2023 | Perseris |
| Gilead Sciences, INC. | $18.27 | 2022 | |
| Collegium Pharmaceutical, INC. | $14.67 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.